Your browser is no longer supported. Please, upgrade your browser.
NKTR Nektar Therapeutics monthly Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E9.22 EPS (ttm)3.52 Insider Own0.60% Shs Outstand180.86M Perf Week-6.75%
Market Cap5.88B Forward P/E- EPS next Y-2.70 Insider Trans-26.54% Shs Float173.06M Perf Month-2.72%
Income658.60M PEG- EPS next Q-0.80 Inst Own94.80% Short Float13.13% Perf Quarter-2.99%
Sales1.18B P/S4.97 EPS this Y289.50% Inst Trans-0.03% Short Ratio14.33 Perf Half Y-21.75%
Book/sh9.40 P/B3.46 EPS next Y12.40% ROA29.70% Target Price69.91 Perf Year-32.02%
Cash/sh7.68 P/C4.23 EPS next 5Y-7.30% ROE37.60% 52W Range29.22 - 69.76 Perf YTD-1.16%
Dividend- P/FCF8.76 EPS past 5Y36.30% ROI34.90% 52W High-53.43% Beta2.66
Dividend %- Quick Ratio14.80 Sales past 5Y51.60% Gross Margin98.00% 52W Low11.19% ATR1.23
Employees618 Current Ratio14.90 Sales Q/Q-25.80% Oper. Margin55.30% RSI (14)41.50 Volatility3.58% 3.88%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.50% Profit Margin55.60% Rel Volume1.39 Prev Close33.21
ShortableYes LT Debt/Eq0.15 EarningsAug 07 AMC Payout0.00% Avg Volume1.59M Price32.49
Recom1.90 SMA20-6.39% SMA50-3.65% SMA200-14.28% Volume2,197,547 Change-2.17%
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
Jul-15-19 12:44PM  Nektar Therapeutics Stock Poised for Significant Move Investopedia
Jul-12-19 08:15PM  Nektar Therapeutics Inc (NKTR) SVP & CFO Gil M Labrucherie Sold $864,250 of Shares GuruFocus.com
Jul-08-19 06:46PM  Here's Why Nektar Therapeutics Stock Gained 13.6% in June Motley Fool
Jun-23-19 04:42PM  Is Nektar Therapeutics (NKTR) A Good Stock To Buy? Insider Monkey
Jun-21-19 06:00AM  Nektar's Drug Could be a "Big Deal" MoneyShow
Jun-19-19 01:58PM  Harry Boxers three biotech stocks on the move include Nektar Therapeutics MarketWatch
Jun-14-19 12:42PM  Should We Be Delighted With Nektar Therapeutics's (NASDAQ:NKTR) ROE Of 40%? Simply Wall St.
07:22AM  3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics InvestorPlace
Jun-13-19 07:44AM  The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes Benzinga
06:45AM  First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology PR Newswire
Jun-11-19 12:50PM  Edited Transcript of NKTR earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents
09:00AM  Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019) PR Newswire
07:00AM  Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now? Zacks
Jun-08-19 04:09PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
Jun-07-19 09:30AM  Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound? Zacks
Jun-05-19 03:11PM  Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
Jun-04-19 08:39AM  Nektar (NKTR) in Focus: Stock Moves 8.8% Higher Zacks
Jun-03-19 04:31PM  Why El Paso Electric, Nektar Therapeutics, and Hecla Mining Jumped Today Motley Fool +8.75%
04:24PM  Who Are The Winners And Losers From The Year's Biggest Cancer Meeting? Investor's Business Daily
02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
12:41PM  Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study TheStreet.com
Jun-01-19 09:00AM  Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting PR Newswire
May-31-19 03:45PM  How To Know Whats In Your ETF ETF.com
08:57AM  These 6 stocks in the S&P 500 are down at least 50% and analysts say buy MarketWatch
May-25-19 10:19AM  What Is Nektar Therapeutics' New Game Plan? Motley Fool
May-24-19 09:56AM  Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary Zacks
May-23-19 05:29PM  Why this pain-killing opioid is spinning into a new company American City Business Journals
08:00AM  Nektar Announces the Launch of Inheris Biopharma, Inc. PR Newswire
May-22-19 07:29AM  Jim Cramer Weighs In On Nektar, L Brands And More Benzinga
May-21-19 07:06PM  Cramer's lightning round: McDonald's is 'one of the greatest stocks of our time' CNBC
May-16-19 04:07PM  6 Positions the Vanguard Health Care Fund Continues to Increase GuruFocus.com -7.55%
May-15-19 05:00PM  Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting PR Newswire
May-10-19 09:55AM  3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates Zacks
May-09-19 04:08PM  This Biotech Stock Is Flying As Cancer Update, Opioid Approval Loom Investor's Business Daily +7.49%
02:33PM  Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks
07:00AM  What You'll Want to Know About Nektar Therapeutics' Q1 Earnings Results Motley Fool
12:23AM  Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 05:45PM  Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:35PM  Nektar: 1Q Earnings Snapshot Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the First Quarter of 2019 PR Newswire
May-07-19 03:31PM  Nektar Therapeutics Expected to Lose 69 Cents a Share TheStreet.com
09:35AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
May-02-19 10:33AM  Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
May-01-19 05:00PM  Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets PR Newswire
Apr-28-19 05:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Apr-24-19 02:55PM  S&P 500 closes at record high, even as EPS growth stagnates Reuters
Apr-23-19 06:56PM  S&P 500 closes at record high, even as EPS growth stagnates Reuters
Apr-22-19 10:42AM  Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)? Insider Monkey
Apr-12-19 03:26PM  These 3 Falling Knives Are Expected to Outperform GuruFocus.com
Apr-11-19 10:57AM  Analysts believe the stock market will set a record soon and these names are going to lead the way CNBC
Apr-03-19 04:38PM  GameStop falls while Dave & Buster's and Blue Apron rise Associated Press
11:50AM  A Look At Nektar Therapeutics's (NASDAQ:NKTR) Exceptional Fundamentals Simply Wall St.
Apr-02-19 03:00PM  Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 PR Newswire
07:30AM  The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial Benzinga
Apr-01-19 04:43PM  Here are the typical employee salaries at Twitter, Salesforce, Yelp, Square, Zynga, Dolby and other tech companies American City Business Journals
04:15PM  Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019 PR Newswire
Mar-30-19 09:30AM  Nektar (NKTR) Down 17.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-12-19 06:00AM  3 Stocks That Could Double Your Money Motley Fool
Mar-07-19 09:49AM  Stock Market News For Mar 7, 2019 Zacks
12:02AM  Edited Transcript of NKTR earnings conference call or presentation 28-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Mar-06-19 04:30PM  Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference PR Newswire -5.23%
06:28AM  Biotech Companies Slump Midday With FDA Chief Set to Leave Investing.com
Mar-05-19 08:15AM  Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-04-19 08:00AM  BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer GlobeNewswire
Mar-01-19 10:48PM  Nektar Therapeutics Inc (NKTR) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com -5.94%
04:40PM  Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting PR Newswire
12:14PM  Stocks making the biggest moves midday: Gap, Tesla, L Brands & more CNBC
09:26AM  Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended Zacks
09:00AM  Nektar Therapeutics (NKTR) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-28-19 04:10PM  Nektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results PR Newswire
03:00PM  Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Feb-27-19 04:35PM  Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 PR Newswire
02:03PM  Nektar Therapeutics Expected to Lose 55 Cents a Share TheStreet.com
07:28AM  7 Fundamental Plays for a Stock Picker Market Investopedia
Feb-25-19 05:00PM  Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium PR Newswire
07:57AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
Feb-21-19 04:30PM  Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets PR Newswire -6.44%
12:10PM  Is Nektar Therapeutics (NASDAQ:NKTR) A Financially Strong Company? Simply Wall St.
Feb-18-19 01:49PM  Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed the Company According to Shareholder Lawsuit Business Wire
Feb-17-19 09:12AM  3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys? Motley Fool
Feb-15-19 03:15PM  Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients Reuters
03:15PM  Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium PR Newswire
07:35AM  Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit New Research Emphasizes Economic Growth GlobeNewswire
Feb-14-19 05:24AM  8 Stocks That Can Lead in a 'Micro-Driven' Market Investopedia
Feb-12-19 03:02PM  9 U.S. Stocks That Are Coming to Life Again InvestorPlace -8.82%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 05:14PM  Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium PR Newswire
01:49PM  Why Nektar Therapeutics Stock Gained 29% in January Motley Fool
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-27-19 11:05AM  5 "Strong Buy" Stock Picks for 2019 (That Crashed in 2018) Kiplinger
Jan-26-19 10:05AM  Is Bristol-Myers Squibb a Bargain Now? Motley Fool
Jan-15-19 07:11AM  These beaten-down stocks are expected to roar back in 2019 MarketWatch +7.23%
Jan-14-19 08:46PM  Here's Why Nektar Therapeutics Gave Back 45% in 2018 Motley Fool
Jan-08-19 05:28PM  Here's Why Nektar Therapeutics Surged Today Motley Fool +11.09%
10:03AM  Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close Investing.com
Jan-03-19 07:00AM  Today's Research Reports on Trending Tickers: Celgene and Nektar Therapeutics ACCESSWIRE -7.71%
07:00AM  ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics PR Newswire
Dec-31-18 12:50PM  DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:09AM  CLASS ACTION UPDATE for NKTR, FIT, WBT and XRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
Nektar Therapeutics develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc. Nektar Therapeutics also has a research collaboration with Trovagene, Inc. for the treatment of metastatic colorectal cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Option Exercise7.2125,000180,250152,935Jul 12 06:31 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Sale34.5725,000864,250127,935Jul 12 06:31 PM
Lingnau LutzDirectorJul 08Option Exercise9.2410,00092,40033,200Jul 10 05:34 PM
Lingnau LutzDirectorJul 08Sale34.6310,000346,30023,200Jul 10 05:34 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Option Exercise7.2125,000180,250152,935Jun 19 05:50 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Sale33.7125,000842,750127,935Jun 19 05:50 PM
ROBIN HOWARD WPresident & CEOMay 23Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 23Sale32.6933,3331,089,656295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Option Exercise7.2133,334240,338328,660May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Sale33.3833,3341,112,689295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Sale32.9333,3331,097,656295,326May 23 07:19 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale31.371,92860,481164,463May 17 08:22 PM
ROBIN HOWARD WPresident & CEOMay 16Sale31.3713,383419,825295,326May 17 08:22 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale31.373,767118,171127,935May 17 08:20 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale31.374,077127,895166,578May 17 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale31.372,44976,82594,694May 17 08:19 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale31.373,461108,57295,913May 17 08:18 PM
GREER R SCOTTDirectorMar 08Option Exercise5.1410,00051,400145,083Mar 12 06:18 PM
ROBIN HOWARD WPresident & CEOFeb 21Option Exercise7.2133,333240,331342,042Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 21Sale41.0133,3331,366,986308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Option Exercise7.2133,334240,338342,043Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Sale43.2033,3341,440,029308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 19Option Exercise7.2133,333240,331350,924Feb 21 08:16 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 19Sale42.393,592152,265131,702Feb 21 08:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 19Sale42.392,386101,14397,143Feb 21 08:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 19Sale42.393,310140,31199,374Feb 21 08:13 PM
ROBIN HOWARD WPresident & CEOFeb 19Sale42.3342,2151,787,161308,709Feb 21 08:16 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 19Sale42.391,80876,641166,391Feb 21 08:17 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 19Sale42.393,822162,015170,655Feb 21 08:15 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Option Exercise10.6916,119172,312184,318Feb 06 07:17 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Sale42.1616,119679,577168,199Feb 06 07:17 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Option Exercise10.6963,000673,470237,477Jan 30 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Sale42.8263,0002,697,660174,477Jan 30 06:02 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale38.254,016153,612157,249Nov 19 06:15 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale38.255,982228,812174,477Nov 19 06:14 PM
ROBIN HOWARD WPresident & CEONov 16Sale38.2515,326586,220249,141Nov 19 06:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale38.254,694179,54681,029Nov 19 06:12 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale38.256,515249,199106,544Nov 19 06:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale38.254,524173,04378,734Nov 19 06:11 PM
Ajer Jeffrey RobertDirectorSep 20Sale56.766,750383,13015,750Sep 21 07:29 PM
Lingnau LutzDirectorSep 20Sale56.989,000512,82018,450Sep 21 07:32 PM
CHESS ROBERTDirectorSep 19Sale56.814,500255,645269,723Sep 21 07:31 PM
GREER R SCOTTDirectorSep 04Option Exercise5.1410,00051,400140,333Sep 06 07:12 PM
GREER R SCOTTDirectorSep 04Sale67.3910,000673,900130,333Sep 06 07:12 PM
WINGER DENNIS LDirectorAug 21Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 21Sale60.3015,000904,50042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Sale59.6215,000894,30042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 14Sale60.1517,1251,030,06942,750Aug 15 07:30 PM
WINGER DENNIS LDirectorAug 13Sale61.0417,1251,045,31059,875Aug 15 07:30 PM